White paper - Cancer medicines shortages in Europe

May 17, 2017

Access to medicines for cancer patients is crucial for providing high quality care. However, cancer medicines shortages are a problem affecting countries across Europe. These shortages occur when the supply of medicines, identified as essential by the health system, is insufficient to meet public health and patient needs.

Spotlight

Burrard Pharmaceuticals

Burrard Pharmaceuticals is an international leading biopharmaceutical company. We have access to modern state-of-the-art pharmaceutical facilities. The operational efficiency of our facility results in diverse production options, reduced lifecycle costs and compliance to all pharma GMP regulations. We have extensive expert resources combining unique processes and full technology integration. Since our founding in 2005, we are at the forefront of drug manufacturing and technology transfer.

OTHER WHITEPAPERS
news image

Pharma 2020: Marketing the future. Which path will you take?

whitePaper | August 8, 2021

If Pharma is to create a new marketing and sales model that is fit for 2020, it will have to begin by analysing its own value chain to identify opportunities for working more closely with healthcare payers and providers. It will, for example, have to collaborate much more closely with payers (be they governments, health insurers, employers or patients) to ensure that it develops medicines which have real social and economic value.

Read More
news image

Reimagining the pharma landscape with design thinking

whitePaper | July 29, 2021

As pharma companies strive for increased commercial success the customer-centric focus can get lost in the adoption of new commercial endeavours. As a result, many have been looking toward the world of design as a way of enhancing their customer engagement and accelerating their position in the market.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

Pharmaceutical Sales Strategies Post-COVID-19: The Benefits of Virtual Engagement

whitePaper | April 7, 2021

In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges. One solution for these challenges is to engage HCPs – virtually.

Read More
news image

How IPD Can Deliver for Life Sciences

whitePaper | January 1, 2020

Life sciences is facing a number of disruptors: novel cell and gene therapies that will revolutionize manufacturing, drug delivery and pricing models; a battle for the best and brightest talent; political and public pressure on the price of medication as well as the implications of the fourth industrial revolution. These factors combine to make investment decisions more challenging. With life sciences firms placing an increasing focus on the most efficient use of capital and shorter delivery times, project delivery providers are striving to come up with leaner and more innovative strategies and solutions to meet these needs. Integrated Project Delivery (IPD) is one such strategy.

Read More
news image

THE PHARMACEUTICAL INDUSTRY AND GLOBAL HEALTH

whitePaper | January 31, 2022

COVID-19 is an infectious disease caused by a newly discovered coronavirus, which was first identified in December 2019.

Read More

Spotlight

Burrard Pharmaceuticals

Burrard Pharmaceuticals is an international leading biopharmaceutical company. We have access to modern state-of-the-art pharmaceutical facilities. The operational efficiency of our facility results in diverse production options, reduced lifecycle costs and compliance to all pharma GMP regulations. We have extensive expert resources combining unique processes and full technology integration. Since our founding in 2005, we are at the forefront of drug manufacturing and technology transfer.

Events